Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2007-08-21
2007-08-21
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S648000, C514S725000
Reexamination Certificate
active
10229649
ABSTRACT:
Methods and compositions for the treatment of anti-estrogen resistant breast cancer using retinoid compounds which are modulators of Retinoid X Receptors.
REFERENCES:
patent: 4193931 (1980-03-01), Loeliger
patent: 4326055 (1982-04-01), Loeliger
patent: 4539134 (1985-09-01), Martin et al.
patent: 4578498 (1986-03-01), Frickel et al.
patent: 4801733 (1989-01-01), Wuest et al.
patent: 4831052 (1989-05-01), Shudo
patent: 4833240 (1989-05-01), Maignan et al.
patent: 4874747 (1989-10-01), Shroot et al.
patent: 4877805 (1989-10-01), Kligman
patent: 4879284 (1989-11-01), Lang et al.
patent: 4888342 (1989-12-01), Kligman
patent: 4889847 (1989-12-01), Kligman et al.
patent: 4898864 (1990-02-01), Maignan et al.
patent: 4925979 (1990-05-01), Shudo
patent: 4981784 (1991-01-01), Evans et al.
patent: RE33533 (1991-02-01), Shroot et al.
patent: 5004730 (1991-04-01), Philippe et al.
patent: 5071773 (1991-12-01), Evans et al.
patent: 5124473 (1992-06-01), Shroot et al.
patent: 5198567 (1993-03-01), Lang et al.
patent: 5298429 (1994-03-01), Evans et al.
patent: 5391569 (1995-02-01), Brion et al.
patent: 5399586 (1995-03-01), Davies et al.
patent: 5409930 (1995-04-01), Spada et al.
patent: 5455265 (1995-10-01), Chandraratna
patent: 5466861 (1995-11-01), Dawson et al.
patent: 5506102 (1996-04-01), McDonnell
patent: 5508456 (1996-04-01), Boehm
patent: 5514821 (1996-05-01), Bennani et al.
patent: 5552271 (1996-09-01), Pfahl et al.
patent: 5585244 (1996-12-01), Allegretto et al.
patent: 5656643 (1997-08-01), Spada et al.
patent: 5710158 (1998-01-01), Myers et al.
patent: 5721103 (1998-02-01), Boehm et al.
patent: 5770378 (1998-06-01), Hwang et al.
patent: 5770382 (1998-06-01), Hwang et al.
patent: 5770383 (1998-06-01), Hwang et al.
patent: 5780676 (1998-07-01), Boehm et al.
patent: 5801253 (1998-09-01), Klaus et al.
patent: 5817845 (1998-10-01), White et al.
patent: 5824484 (1998-10-01), Pfahl et al.
patent: 5837725 (1998-11-01), Dawson et al.
patent: 5932622 (1999-08-01), Evans et al.
patent: 5962731 (1999-10-01), Boehm et al.
patent: 5968989 (1999-10-01), Evans et al.
patent: 5972881 (1999-10-01), Heyman et al.
patent: 5998654 (1999-12-01), Boehm et al.
patent: 6028052 (2000-02-01), Heyman et al.
patent: 6043279 (2000-03-01), Boehm et al.
patent: 6083977 (2000-07-01), Boehm et al.
patent: 6218430 (2001-04-01), Allegretto et al.
patent: 6228862 (2001-05-01), Heyman et al.
patent: 6316404 (2001-11-01), Heyman et al.
patent: 6320074 (2001-11-01), Boehm et al.
patent: 6521633 (2003-02-01), Heyman et al.
patent: 6545049 (2003-04-01), Canan-Koch et al.
patent: 6576676 (2003-06-01), Evans et al.
patent: 6593493 (2003-07-01), Ardecky et al.
patent: 6610883 (2003-08-01), Boehm et al.
patent: 2034220 (1991-01-01), None
patent: 0 718 285 (1996-06-01), None
patent: WO89/05355 (1989-06-01), None
patent: WO91/06677 (1991-05-01), None
patent: WO92/05477 (1992-04-01), None
patent: WO92/20642 (1992-11-01), None
patent: WO93/03944 (1993-03-01), None
patent: WO93/10094 (1993-05-01), None
patent: WO93/11235 (1993-06-01), None
patent: WO93/11755 (1993-06-01), None
patent: WO93/21146 (1993-10-01), None
patent: WO93/23431 (1993-11-01), None
patent: WO94/15902 (1994-07-01), None
patent: WO94/20093 (1994-09-01), None
patent: WO94/23068 (1994-10-01), None
patent: WO95/04036 (1995-02-01), None
patent: WO95/15758 (1995-06-01), None
patent: WO95/18380 (1995-07-01), None
patent: WO96/05165 (1996-02-01), None
patent: WO96/19458 (1996-06-01), None
patent: WO96/20913 (1996-07-01), None
patent: WO97/12853 (1997-04-01), None
patent: 99/08682 (1999-02-01), None
Pfahl, retinoid related molecules: new promises against lung and breast cancer, Exp. Opin. Invest. Drugs (Apr. 1998), 7(4), pp. 601-606.
Fitzgerald et al., Cancer Research, vol. 57, No. 13, (Jul. 1, 1997), pp. 2642-2650.
Allegretto, E., et al., “Retinoid X Receptor Acts as a Hormone Receptor In Vivo to Induce a Key Metabolic Enzyme for 1,25-Dihydroxyvitamin D3,”J. Bio. Chem., 270(41):23906-23909 (1995).
Antras, et al., “Adipsin Gene Expression in 3T3-F442A Adipocytes Is Posttranscriptionally Down-Regulated by Retinoic Acid,”J. Bio. Chem., 266(2):1157-1161 (1991).
Beard, et al., “Synthesis and Structure-Activity Relationships of Stilbene Analogs Substituted with Heteromatic Carboxylic Acids,”J. Med. Chem., 38:2820-2829 (1995).
Bischoff, et al.,Cancer Research, 58(3):479-484 (1998).
Bissonnette, R., et al., “9-cisRetinoic Acid Inhibition of Activation-Induced Apoptosis Is Mediated via Regulation of Fas Ligand and Requires Retinoic Acid Receptor and Retinoid X Receptor Activation,”Mollecular and Cellular Biology, 15(10):5576-5585 (1995).
Boehm, M., et al.,J. Med. Chem., 37:2930 (994).
Boehm, M., et al., “Design and Synthesis of Potent Retinoid X Receptor Selective Ligands That Induce Apoptosis in Leukemia Cells,”J. Med. Chem., 38(16):3146-3155 (1995).
Canan Koch, S. et al., “Identification of the First Retinoid X Receptor Homodimer Antagonist,”J. Med. Chem., 39(17):3229-3234 (1996).
Dawson, M., et al., “Effect of Structural Modifications in the C7-C11 Region of the Retinoid Skeleton on Biological Activity in a Series of Aromatic Retinoids,”J. Med. Chem., 32:1504-1517 (1989).
Dawson, M., et al.,Chemistry and Biology of Synthetic Retinoids, Chapters 3, 8, 14, and 16, CRC Press, Inc., Florida (1990).
Dawson, M., et al., “The Synthetic Chemistry of Retinoids,”The Retiniods: Biology, Chemistry and Medicine, Raven Press, pp. 5-178 (1994).
Evans, et al., “The Steroid and Thyroid Hormone Receptor Superfamily,”Science, 240:889-895 (1988).
Fingl, E., et al., “General Principles,”The Pharmacological Basis of Therapeutics, pp. 1-46 (1975).
Fitzgerald, et al.,Cancer Research, 57(13):2642-2650 (1997).
Gennaro, Alfonso, R., et al.,Remmington's Pharmaceutical Sciences, 18thEdition, Mack Publishing Co., Easton PA (1990).
Giguere, V., et al., “Identification of a Receptor for the Morphogen Retinoic Acid,”Nature, 330(17):624-629 (1987).
Gottardis, M., et al., “Chemoprevention of Mammary Carcinoma by LGD1069 (Targretin): An RXR-Selective Ligand,”Cancer Research, 56:5566-5570 (1996).
Heyman, R., et al., “9-Cis Retinoic Acid is a High Affinity Ligand for the Retinoid X Receptor,”Cell, 68:397-406 (1992).
Kagechika, H., et al., “Retinobenzoic Acids. 2. Structure-Activity Relationships of Chalcone-4-Carboxylic Acids and Flavone-4′-Carboxylic Acids,”J. Med. Chem., 32:834-840 (1989).
Kagechika, H., et al., “Retinobenzoic Acids. 3. Structure-Activity Relationships of Retinoidal Azobenzene-4-Carboxylic Acids and Stilbene-4-Carboxylic Acids,”J. Med. Chem., 32:1098-1108 (1989).
Kagechika, H., et al., “Retinobenzoic Acids. 4. Conformation of Aromatic Amides with Retinoidal Activity. Importance oftrans-Amide Structure for the Activity,”J. Med. Chem., 32:2292-2296 (1989).
Levin, A., et al., “9-CisRetinoic Acid Stereoisomer Binds and Activated the Nuclear Receptor RXRα,”Nature, 355:359-361 (1992).
Liu, R., et al., “Photochemistry and Synthesis of Stereoisomers of Vitamin A,”Tetrahedron Letters, 40(11):1931-1969 (1984).
Loeliger, P., et al., “Arotinoids, A New Class of Highly Active Retinoids,”Eur. J. Med. Chem., 1:9-15 (1980).
Mangelsdorf, D., et al., “A Direct Repeat in the Cellular Retinol-Binding Protein Type II Gene Confers Differential Regulation by RXR and PAR,”Cell, 66:555-561 (1991).
Mangelsdorf, D., et al., “The Retinoid Receptors,”The Retiniods: Biology, Chemistry and Medicine, Raven Press, pp. 319-349 (1994).
Miller, et al.,J. Clinical Oncology, 15(2)790-795 (1997).
Petkovich, M., et al., “A Human Retinoic Acid Receptor Which Belongs to the Family of Nuclear Receptors,”Nature, 330:444-450 (1987).
Pfahl, M., “Retinoid Related Molecules: New Promises Against Lung and Breast Cancer,”Exp. Opin. Invest. Drugs, 7(4):601-606 (1998).
Safonova, I., et al., “Retinoids are posi
Bischoff Eric D.
Heyman Richard A.
Lamph William W.
Anderson James D.
Fish & Richardson P.C.
Llgand Pharmaceuticals Incorporated
Miskiel Frank J.
Seidman Stephanie
LandOfFree
Methods and pharmaceutical compositions for treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and pharmaceutical compositions for treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and pharmaceutical compositions for treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3894955